Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April A N Rose

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMBApril A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancerApril A N Rose, Andrée-Anne Grosset, Zhifeng Dong, et al.
The Journal of Investigative Dermatology|April 8, 2021
Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like MelanomaThiago P Muniz, Hadas Sorotsky, Yada Kanjanapan, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-AnalysisMatthew Dankner, Laurie-Rose Dubé, Mark Sorin, et al.
Journal for Immunotherapy of Cancer|January 23, 2021
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapyApril A N Rose, Susan M Armstrong, David Hogg, et al.
Heliyon|May 3, 2024
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysissDavid J H Bian, Anna-Maria Lazaratos, Sarah M Maritan, et al.
Cancers|November 13, 2025
Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate CancerSoumaya Labidi, Belinda Jiao, Shirley Tam, et al.
Cell Reports|April 6, 2022
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapyShivshankari Rajkumar, Diana Berry, Kayla A Heney, et al.
BMJ Open|March 29, 2024
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort studySoumaya Labidi, Nicholas Meti, Reeta Barua, et al.
Cell Death & Disease|May 6, 2026
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathwayFeiyang Cai, Fan Huang, Christophe Goncalves, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMBApril A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancerApril A N Rose, Andrée-Anne Grosset, Zhifeng Dong, et al.
The Journal of Investigative Dermatology|April 8, 2021
Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like MelanomaThiago P Muniz, Hadas Sorotsky, Yada Kanjanapan, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-AnalysisMatthew Dankner, Laurie-Rose Dubé, Mark Sorin, et al.
Journal for Immunotherapy of Cancer|January 23, 2021
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapyApril A N Rose, Susan M Armstrong, David Hogg, et al.
Heliyon|May 3, 2024
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysissDavid J H Bian, Anna-Maria Lazaratos, Sarah M Maritan, et al.
Cancers|November 13, 2025
Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate CancerSoumaya Labidi, Belinda Jiao, Shirley Tam, et al.
Cell Reports|April 6, 2022
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapyShivshankari Rajkumar, Diana Berry, Kayla A Heney, et al.
BMJ Open|March 29, 2024
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort studySoumaya Labidi, Nicholas Meti, Reeta Barua, et al.
Cell Death & Disease|May 6, 2026
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathwayFeiyang Cai, Fan Huang, Christophe Goncalves, et al.
Pageof 5